Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03636438 · ClinicalTrials.gov registry record
Long Term Follow Up to Evaluate DTX301 in Adults With Late-Onset OTC Deficiency
A clinical trial of Ornithine Transcarbamylase (OTC) Deficiency, sponsored by Ultragenyx Pharmaceutical.
- Active
- Registry status
- 11
- Enrollment target
- 9
- Study locations
NCT03636438 is a study of Ornithine Transcarbamylase (OTC) Deficiency that is active but no longer recruiting, run by Ultragenyx Pharmaceutical. The registered enrollment target is 11 participants. The trial reports 9 study locations across 9 states.
The verdict
NCT03636438, a study of Ornithine Transcarbamylase (OTC) Deficiency, is active but no longer recruiting, sponsored by Ultragenyx Pharmaceutical.
- ACTIVE NOT RECRUITING
- Registry status
- 11 participants
- Enrollment target
- 9
- Study locations
Study Summary
Determine the long-term safety of DTX301 following a single intravenous (IV) dose in adults with late-onset ornithine transcarbamylase (OTC) deficiency.
Conditions Studied
Interventions
- OTHER No Intervention
Study Locations (9)
Colorado
- The Children's Hospital Colorado - Aurora
Massachusetts
- Boston Children's Hospital - Boston
New York
- Icahn School of Medicine - New York
Ohio
- University Hospital Cleveland Medical Center/Case Western Reserve University - Cleveland
Alberta
- M.A.G.I.C. Clinic - Calgary
Rhone
- Hopital Femme Mere Enfant - Bron
Coruna
- Hospital Clinico Universitario de Santiago - Santiago de Compostela
Vizcaya
- Hospital Universitario de Cruces. Servicio de Pediatria - Barakaldo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2018-08-30 |
| Est. Completion | 2029-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03636438
The ClinicalTrials.gov registry entry for NCT03636438 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ultragenyx Pharmaceutical, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Ornithine Transcarbamylase (OTC) Deficiency appearing as the primary indexed condition, and to 1 intervention - of which No Intervention is the first listed.
NCT03636438 reports 9 study locations spanning 9 distinct geographic areas - top geographies include Colorado, Massachusetts, New York.
Frequently Asked Questions
What is clinical trial NCT03636438 about?
NCT03636438 is a clinical study titled "Long Term Follow Up to Evaluate DTX301 in Adults With Late-Onset OTC Deficiency". Determine the long-term safety of DTX301 following a single intravenous (IV) dose in adults with late-onset ornithine transcarbamylase (OTC) deficiency.
What is the current status of trial NCT03636438?
This trial is currently active not recruiting. The enrollment target is 11 participants. The study started on 2018-08-30. Estimated completion is 2029-12.
What conditions does trial NCT03636438 study?
This clinical trial studies the following conditions: Ornithine Transcarbamylase (OTC) Deficiency.
What interventions are being tested in trial NCT03636438?
The interventions under investigation include: No Intervention (OTHER).
Who is sponsoring clinical trial NCT03636438?
This trial is sponsored by Ultragenyx Pharmaceutical, which has 52 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03636438 being conducted?
This trial has 9 study locations across Colorado, Massachusetts, New York, Ohio, Alberta. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ornithine Transcarbamylase (OTC) Deficiency
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.